Cellular landscaping of cisplatin resistance in cervical cancer

Bhattacharjee, Rahul; Dey, Tanima; Kumar, Lamha; Kar, Sulagna; Sarkar, Ritayan; Ghorai, Mimosa; Malik, Sumira; Jha, Niraj Kumar; Vellingiri, Balachandar; Kesari, Kavindra Kumar; Lastra, José Manuel Pérez de la; Dey, Abhijit

doi:10.1016/j.biopha.2022.113345

Cited by 37 publications

(28 citation statements)

References 254 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bhattacharya et al used multifunctional GNPs as a potential treatment for ovarian cancer. Compared to normal cell lines, malignant cells (OV‐167, OVCAR 5) were more susceptible to the deleterious effects of gold nanoparticles in combination with thiolated polyethylene glycol (HS‐PEG), cisplatin, 96 and folic acid (HUVECs, OSE) 97,98 …”

Section: Metal Inorganic Nanoparticlesmentioning

confidence: 99%

“…Bhattacharya et al used multifunctional GNPs as a potential treatment for ovarian cancer. Compared to normal cell lines, malignant cells (OV-167, OVCAR 5) were more susceptible to the deleterious effects of gold nanoparticles in combination with thiolated polyethylene glycol (HS-PEG), cisplatin, 96 and folic acid (HUVECs, OSE). 97,98 For the clinical use of nanoparticles, a fundamental understanding of their behaviour in the tumour microenvironment is essential to improve their effectiveness as therapeutic and diagnostic agents.…”

Section: Jia Et Al Synthesized 'Bio-friendly Virus'-like Gnps By Scat...mentioning

confidence: 99%

See 1 more Smart Citation

Nano‐biotechnology in tumour and cancerous disease: A perspective review

Soni

Bhandari

Tripathi

et al. 2023

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

In recent years, drug manufacturers and researchers have begun to consider the nanobiotechnology approach to improve the drug delivery system for tumour and cancer diseases. In this article, we review current strategies to improve tumour and cancer drug delivery, which mainly focuses on sustaining biocompatibility, biodistribution, and active targeting. The conventional therapy using cornerstone drugs such as fludarabine, cisplatin etoposide, and paclitaxel has its own challenges especially not being able to discriminate between tumour versus normal cells which eventually led to toxicity and side effects in the patients. In contrast to the conventional approach, nanoparticle-based drug delivery provides target-specific delivery and controlled release of the drug, which provides a better therapeutic window for treatment options by focusing on the eradication of diseased cells via active targeting and sparing normal cells via passive targeting. Additionally, treatment of tumours associated with the brain is hampered by the impermeability of the blood-brain barriers to the drugs, which eventually led to poor survival in the patients. Nanoparticle-based therapy offers superior delivery of drugs to the target by breaching the blood-brain barriers. Herein, we provide an overview of the properties of nanoparticles that are crucial for nanotechnology applications. We address the potential future applications

show abstract

Section: Metal Inorganic Nanoparticlesmentioning

confidence: 99%

Section: Jia Et Al Synthesized 'Bio-friendly Virus'-like Gnps By Scat...mentioning

confidence: 99%

Nano‐biotechnology in tumour and cancerous disease: A perspective review

Soni

Bhandari

Tripathi

et al. 2023

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cisplatin (CDDP)-based chemotherapy is a standard treatment for many cancers [ 1 ]. However, resistance to chemotherapy is associated with poor survival [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments

Zhang

Song

Dai

et al. 2023

Cancers

View full text Add to dashboard Cite

In recent years, chemoimmunotherapy has become effective in some advanced cancers, but its effect is still limited. Transcriptional upregulation of isocitrate dehydrogenase 3α (IDH3α) can promote tumor initiation and progression. However, it is not clear whether the aberrant expression of IDH3α is related to the efficacy of chemoimmunotherapy in cancers. Here, we found that IDH3α was elevated in uterine cervical cancer (UCC) and lung adenocarcinoma (LUAD) samples by using public databases. High expression of IDH3α could promote the epithelial–mesenchymal transition (EMT), alter the intracellular redox status, promote glycolysis, and induce an acidic microenvironments in cancer cells. Furthermore, we found that inhibition of IDH3α combined with chemoimmunotherapy (cisplatin and programmed cell death ligand 1 (PD-L1) antibodies) activated the cGAS–STING pathway, promoted CD8+ T cell infiltration, and decreased tumor growth in mouse models of cervical cancer. In conclusion, our data indicate that silencing IDH3α sensitizes tumors to chemoimmunotherapy by modulating the acidic microenvironment and activating the cGAS–STING pathway.

show abstract

“…HPV infection has a significant occurrence in the majority of cervical cancers ( 5 ). According to the GLOBOCAN reports, the third most predominant cancer in women is cervical cancer ( 6 ). There were an estimated 604,127 cases of cervical cancer reported worldwide in 2020, which accounts for 3.1% of the global cancer cases.…”

Section: Introductionmentioning

confidence: 99%

Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs

et al. 2022

Self Cite

View full text Add to dashboard Cite

Human papillomavirus (HPV) contributes to sexually transmitted infection, which is primarily associated with pre-cancerous and cancerous lesions in both men and women and is among the neglected cancerous infections in the world. At global level, two-, four-, and nine-valent pure L1 protein encompassed vaccines in targeting high-risk HPV strains using recombinant DNA technology are available. Therapeutic vaccines are produced by early and late oncoproteins that impart superior cell immunity to preventive vaccines that are under investigation. In the current review, we have not only discussed the clinical significance and importance of both preventive and therapeutic vaccines but also highlighted their dosage and mode of administration. This review is novel in its way and will pave the way for researchers to address the challenges posed by HPV-based vaccines at the present time.

show abstract

Cellular landscaping of cisplatin resistance in cervical cancer

Cited by 37 publications

References 254 publications

Nano‐biotechnology in tumour and cancerous disease: A perspective review

Nano‐biotechnology in tumour and cancerous disease: A perspective review

Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments

Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs

Contact Info

Product

Resources

About